Automotive

MediLink reports significant overall survival benefit in phase III trial of Tam-Peli for relapsed small-cell lung cancer in Chinese patients, boosting interest.

• Forsale 100 Team
• September 13, 2026

LUXEED held a dedicated engagement session with Chery International Middle East dealer delegation, emphasizing strategic collaboration and brand development.

• Forsale 100 Team
• September 5, 2026

Hyundai Motor America announced its sales figures for August 2026, indicating a notable performance in the U.S. market amid ongoing industry shifts.

• Forsale 100 Team
• September 1, 2026

HUTCHMED announces significant progression-free survival improvements in SANOVO trial combining ORPATHYS® and TAGRISSO® for MET-overexpressing EGFR-mutated lung cancer.

• Forsale 100 Team
• August 31, 2026

INTCO Medical announced a 40.6% revenue increase in H1 2026 and plans to expand glove production capacity to 107 billion units globally.

• Forsale 100 Team
• August 30, 2026

HUTCHMED’s ATLED® (Fanregratinib) gains approval from China’s NMPA for treating FGFR2-fusion intrahepatic cholangiocarcinoma, expanding treatment options.

• Forsale 100 Team
• August 28, 2026

4DMT announces favorable 2-year data from its PRISM Phase 2b trial for wet AMD, showing promising efficacy and safety signals, advancing its development pipeline.

• Forsale 100 Team
• July 19, 2026